RT Journal Article
SR Electronic
T1 Platelet Activating Immune Complexes Identified in COVID-19 Associated Coagulopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.04.20226076
DO 10.1101/2020.11.04.20226076
A1 Nazy, Ishac
A1 Jevtic, Stefan D
A1 Moore, Jane C
A1 Huynh, Angela
A1 Smith, James W
A1 Kelton, John G
A1 Arnold, Donald M
YR 2020
UL http://medrxiv.org/content/early/2020/11/06/2020.11.04.20226076.abstract
AB Thrombosis is a prominent feature of coronavirus disease 2019 (COVID-19) and often occurs in patients who are critically ill; however, the mechanism is unclear. This COVID-19 associated coagulopathy (CAC) shares features with heparin-induced thrombocytopenia (HIT), including mild thrombocytopenia and thrombosis. We thus tested 10 CAC patients for anti-PF4/heparin antibodies and functional platelet activation. HIT was excluded in all samples based on anti-PF4/heparin antibody and serotonin release assay results. Of note, 6 CAC patients demonstrated platelet activation by the serotonin release assay that was inhibited by FcγRIIA receptor blockade, confirming an IgG-specific immune complex (IC)-mediated reaction. Platelet activation was independent of heparin, but inhibitable by both therapeutic and high dose heparin. All 6 samples were positive for IgG-specific antibodies targeting the receptor binding domain (RBD) or the spike protein of the SARS-CoV-2 virus. These samples were additionally characterized by significant endothelial activation, shown by increased von Willebrand factor antigen and activity. ADAMTS13 activity was not severely reduced, and ADAMTS13 inhibitors were not present, ruling out thrombotic thrombocytopenic purpura. Our study thus identifies platelet-activating ICs as a mechanism that contributes to CAC thrombosis.Scientific Category Thrombosis and HemostasisKey PointsPatients with COVID-19 thrombosis have immune complexes that activate platelets through FcγRIIA signallingPatients with COVID-19 thrombosis demonstrate increased VWF antigen and activity that is not related to severe ADAMTS13 reductionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementFunding support for this work was provided by a grant from the Ontario Research Fund (ORF #2426729), COVID-19 Rapid Research Fund awarded to Dr. Ishac Nazy (#VR2-173204), and Academic Health Sciences Organization (HAHSO) grant awarded to Dr. Donald M Arnold (#HAH-21-02).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by Hamilton Integrated Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional data can be obtained by emailing the corresponding author.